Adapts human therapeutics into veterinary products for the animal health market, maintaining a focused pipeline of three major programs. Provides a partnered commercialization model for human life sciences firms that preserves IP control and boosts incremental revenue via translational insights, regulatory efficiency, and shared profitability.